Department of Psychiatry, Stellenbosch University, South Africa.
Department of Psychiatry, Stellenbosch University, South Africa.
Schizophr Res. 2019 Apr;206:171-176. doi: 10.1016/j.schres.2018.11.031. Epub 2018 Nov 30.
Treatment-emergent weight gain is associated with antipsychotic efficacy in schizophrenia patients treated with clozapine and olanzapine. However, few studies have investigated this relationship in first-episode patients treated with other antipsychotics, in particular those with a lower obesogenic potential. Aim To investigate the relationships between weight gain and associated metabolic changes with psychopathology improvement in relation to age, sex, ethnicity, substance use, treatment duration and antipsychotic dose in first-episode schizophrenia spectrum disorder patients.
This single site cohort study included 106 minimally treated or antipsychotic-naive patients treated with flupenthixol decanoate over 12 months. Psychopathology was evaluated using the Positive and Negative Syndrome Scale (PANSS) and BMI, fasting blood lipids and glucose were assessed at regular intervals. Linear regression models were constructed to determine the effects of socio-demographic, clinical and metabolic factors as predictors of change in total PANSS score and factor-derived domains.
BMI change scores were inversely correlated with change in PANSS total (R = -0.25; p = 0.011), positive (R = -0.23; p = 0.019), depressive anxiety (R = -0.21; p = 0.031) and disorganized symptoms (R = -0.32; p < 0.001). Linear regression analysis showed that increased BMI and treatment duration both predicted improvement in global psychopathology and disorganized symptoms independent of age, sex, ethnicity, substance use, co-medication with antidepressants and/or anticholinergics, as well as the dose and duration of antipsychotic exposure.
Our findings suggest that the relationship between treatment-emergent weight gain and psychopathology improvement is not limited to patients treated with antipsychotics most associated with weight gain, and is not confounded by treatment duration and dose.
氯氮平和奥氮平治疗的精神分裂症患者中,出现治疗引起的体重增加与抗精神病药疗效相关。然而,很少有研究调查其他抗精神病药治疗的首发患者,特别是肥胖风险较低的患者中,这种关系。目的:研究首发精神分裂症谱系障碍患者中,体重增加与相关代谢变化与精神病理学改善的关系与年龄、性别、种族、物质使用、治疗持续时间和抗精神病药剂量的关系。
本单中心队列研究纳入了 106 例接受氟奋乃静癸酸酯治疗 12 个月的未经治疗或抗精神病药初治患者。采用阳性和阴性综合征量表(PANSS)评估精神病理学,定期评估 BMI、空腹血脂和血糖。构建线性回归模型,以确定社会人口统计学、临床和代谢因素作为总 PANSS 评分和因子衍生领域变化的预测因子的影响。
体重指数变化评分与 PANSS 总分(R= -0.25;p=0.011)、阳性症状(R= -0.23;p=0.019)、抑郁焦虑(R= -0.21;p=0.031)和精神分裂症状(R= -0.32;p<0.001)变化呈负相关。线性回归分析表明,BMI 增加和治疗持续时间均独立于年龄、性别、种族、物质使用、抗抑郁药和/或抗胆碱能药物的合并用药、以及抗精神病药暴露的剂量和持续时间,预测整体精神病理学和精神分裂症状的改善。
我们的发现表明,治疗引起的体重增加与精神病理学改善之间的关系不仅限于与体重增加最相关的抗精神病药治疗的患者,而且不受治疗持续时间和剂量的影响。